Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 17, 2012New Self-Expanding Nitinol Stent Offers Balance of Flexibility and Radial Strength for Enhanced Performance in Iliac Stenting Procedures
Boston Scientific Corporation (NYSE: BSX) announces U.S. Food and Drug Administration approval and market launch of the Epic™ Vascular Self-Expanding...
-
May 15, 2012Follow-up Data from EVOLVE Trial Presented at EuroPCR; Trial is Evaluating Next-Generation Everolimus-Eluting Platinum Chromium Coronary Stent with Ultra-Thin Bioabsorbable Abluminal Polymer
Boston Scientific Corporation (NYSE: BSX) announces that the SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer-Coated Platinum Chromium Coronary...
-
May 15, 2012Results of REPRISE I Study Suggest Device Minimizes Aortic Regurgitation
Boston Scientific Corporation (NYSE: BSX) announces results from the REPRISE I feasibility trial, which evaluated the acute safety of the Lotus™...
-
May 14, 2012Innovative Stent Designed to Treat Peripheral Vascular Lesions for Stenoses in Arteries above the Knee
Boston Scientific Corporation (NYSE: BSX) announces CE Mark and European market launch of the Innova™ Self-Expanding Bare-Metal Stent System, which...
-
May 14, 2012Collaboration expected to improve access to imaging data used to treat patients
Boston Scientific Corporation (NYSE: BSX) and Royal Philips Electronics (NYSE: PHG, AEX: PHI) announced a collaboration enabling Philips to...
-
May 11, 2012Results Presented at Heart Rhythm Society from ASA Plavix Study Evaluating Boston Scientific Left Atrial Appendage Closure Device
Boston Scientific Corporation (NYSE: BSX) announces results from the ASA Plavix (ASAP) Study, which studied the WATCHMAN® Left Atrial...
-
May 10, 2012Clinical Presentations to Include 12-month Outcomes Data from EVOLVE Trial and Results of the REPRISE I Trial
Boston Scientific Corporation (NYSE: BSX) announces its schedule of major events and sponsored clinical research at the annual EuroPCR Scientific...
-
May 7, 2012Advanced Pacemaker Platform Designed to Treat Chronotropic Incompetence, which Affects up to 42 Percent of Pacemaker Patients
Boston Scientific Corporation (NYSE: BSX) announces U.S. Food and Drug Administration (FDA) approval and market launch of its INGENIO™ and ADVANTIO™...
-
May 3, 2012
Boston Scientific Corporation (NYSE: BSX) announces its schedule of major events and sponsored research at Heart Rhythm 2012, the Heart Rhythm Society's...
-
Apr 26, 2012
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2012 Deutsche Bank Healthcare Conference on May 8 in Boston. Hank...